Non-vitamin K Oral Anticoagulants in Cardioversion

Non-vitamin K Oral Anticoagulants in Cardioversion of Atrial Fibrillation. FinCV3

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02911545

Acronym

FinCV3

Enrollment

1000

Registered

2016-09-22

Start date

2011-10-31

Completion date

2016-05-31

Last updated

2016-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial fibrillation, Anticoagulation, Cardioversion

Brief summary

Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF). There are yet limited real life data on outcomes following elective cardioversion in AF patients treated with NOACs. The aim of this study is to investigate the complications and the use of NOACs in AF patients undergoing cardioversion.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* AF patients undergoing cardioversion

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Incidence and predictors of thromboembolic complications	31 days after cardioversion of persistent AF
Incidence and predictors of bleeding	31 days after cardioversion of persistent AF

Secondary

Measure	Time frame
Number of recurrence of AF	31 days after cardioversion of persistent AF
Hemodynamic complications of cardioversion	31 days after cardioversion of persistent AF

Outcome results